Yang Sheng-Lei, Wang Jing-Xiang, Ma Fei-Er, He Jiang-Hua, Zhang Ao, Sun Xiao-Ming, Wei Ying, Wang Yan
School of Sports Medicine and Rehabilitation, Beijing Sport University, Beijing, China.
Rehabilitation Medicine Center, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China.
Front Nutr. 2025 May 21;12:1590256. doi: 10.3389/fnut.2025.1590256. eCollection 2025.
Osteoporosis (OP) is a common degenerative bone disease that seriously affects the quality of life of patients and poses a significant public health burden. Curcumin (CUR), a natural compound, has attracted much attention due to its anti-inflammatory, antioxidant and bone protective effects. However, there is currently a lack of systematic evaluation of the efficacy and mechanism of CUR in treating OP.
This study is a systematic review and meta-analysis conducted per PRISMA guidelines. Studies meeting the inclusion criteria were retrieved and screened from the PubMed, Embase, Web of Science, and Cochrane Library databases. The included studies were limited to animal models of OP, and the intervention group was treated with a single dose of CUR. A meta-analysis was performed using Review Manager 5.4 and R Studio software. The standardized mean difference (SMD) and 95% confidence interval (CI) were calculated using the fixed-effect or random-effects model. Sources of heterogeneity, sensitivity, and publication bias were also explored.
A total of 17 high-quality studies involving 282 animals were included. The results of the metaanalysis showed that compared with the control group, CUR significantly increased bone mineral density (BMD of the femur: SMD = 2.18, 95% CI: 1.53-2.83; BMD of the tibia: SMD = 1.08, 95% CI: 0.30-1.87), improved the trabecular microstructure (BV/TV: SMD = 2.74, 95% CI: 1.84-3.64; Tb.N: SMD = 2.31, 95% CI: 1.65-2.96; Tb.Th: SMD = 2.09, 95% CI: 1.43-2.76; Tb.Sp: SMD = -2.32, 95% CI: -3.15 to -1.50). In addition, CUR significantly reduced serum CTX-1 and TRAP-5b levels, while increasing OCN and ALP levels. Mechanism studies have shown that CUR may act through OPG/RANKL, Wnt/β-catenin, NF-κB, MAPK, and TGF-β/Smad2/3 signaling pathways.
This study is the first to systematically evaluate CUR's therapeutic effect on an OP animal model. The results show that CUR can significantly improve the pathological state of osteoporosis through a multi-target mechanism and has good therapeutic potential. However, heterogeneity and differences in the quality of the literature suggest that high-quality prospective studies are needed to verify the clinical value of CUR further.
骨质疏松症(OP)是一种常见的退行性骨病,严重影响患者生活质量,给公共卫生带来重大负担。姜黄素(CUR)作为一种天然化合物,因其抗炎、抗氧化和骨保护作用而备受关注。然而,目前对CUR治疗OP的疗效和机制缺乏系统评价。
本研究是一项按照PRISMA指南进行的系统评价和荟萃分析。从PubMed、Embase、Web of Science和Cochrane图书馆数据库中检索并筛选符合纳入标准的研究。纳入的研究仅限于OP动物模型,干预组采用单剂量CUR治疗。使用Review Manager 5.4和R Studio软件进行荟萃分析。采用固定效应或随机效应模型计算标准化均值差(SMD)和95%置信区间(CI)。还探讨了异质性来源、敏感性和发表偏倚。
共纳入17项高质量研究,涉及282只动物。荟萃分析结果显示,与对照组相比,CUR显著提高骨密度(股骨骨密度:SMD = 2.18,95% CI:1.53 - 2.83;胫骨骨密度:SMD = 1.08,95% CI:0.30 - 1.87),改善小梁微观结构(骨体积分数:SMD = 2.74,95% CI:1.84 - 3.64;骨小梁数量:SMD = 2.31,95% CI:1.65 - 2.96;骨小梁厚度:SMD = 2.09,95% CI:1.43 - 2.76;骨小梁间距:SMD = -2.32,95% CI:-3.15至-1.50)。此外,CUR显著降低血清Ⅰ型胶原交联C末端肽(CTX-1)和抗酒石酸酸性磷酸酶5b(TRAP-5b)水平,同时提高骨钙素(OCN)和碱性磷酸酶(ALP)水平。机制研究表明,CUR可能通过骨保护素/核因子κB受体活化因子配体(OPG/RANKL)、Wnt/β-连环蛋白、核因子κB(NF-κB)、丝裂原活化蛋白激酶(MAPK)和转化生长因子β/Smad2/3信号通路发挥作用。
本研究首次系统评价了CUR对OP动物模型的治疗效果。结果表明,CUR可通过多靶点机制显著改善骨质疏松的病理状态,具有良好的治疗潜力。然而,异质性和文献质量差异表明,需要高质量的前瞻性研究进一步验证CUR的临床价值。